Abstract
Two new drugs-bedaquiline and delamanid-have recently been approved by stringent regulatory authorities to treat multidrug-resistant tuberculosis (TB) and recommended by the World Health Organization for use under defined programmatic conditions. Introducing the medications in TB programs worldwide has not kept pace with the need for these drugs. In response, the DR-TB STAT (Drug-Resistant TB Scale-up Treatment Action Team) task force was formed in April 2015 to monitor progress and help overcome challenges. Information was collected from multiple sources and assessed monthly. Some progress has been made in introducing bedaquiline: as of October 2015, a total of 1,258 persons were on the medication under programmatic conditions. For delamanid, >100 patients, but few under programmatic conditions, have received the medication. Coordinated global action might help assist making these medications accessible for persons who need them most.
References
Jul 20, 2007·Bulletin of the World Health Organization·Kai Blöndal
Jun 6, 2009·The New England Journal of Medicine·Andreas H DiaconDavid F Mc Neeley
Jun 8, 2012·The New England Journal of Medicine·Maria Tarcela GlerCharles D Wells
Jul 6, 2012·Therapeutic Advances in Respiratory Disease·Stephen K FieldRobert L Cowie
Sep 7, 2012·PLoS Medicine·Shama D AhujaUNKNOWN Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB
Sep 29, 2012·The European Respiratory Journal·Vija SkripconokaCharles D Wells
Dec 6, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·C R HorsburghUNKNOWN Critical Path to TB Drug Regimens' Access and Appropriate Use Workgroup
Dec 6, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·A ToczekN Ford
Mar 14, 2013·Nursing & Health Sciences·Mojtaba VaismoradiTerese Bondas
Jan 7, 2014·Bulletin of the World Health Organization·Grania BrigdenManica Balasegaram
Jan 24, 2014·Journal of AIDS & Clinical Research·Samuel Om MandaMartie L van der Walt
Mar 29, 2014·The Lancet Infectious Diseases·Alimuddin I ZumlaMarkus Maeurer
May 20, 2014·Bulletin of the World Health Organization·Giovanni Battista Migliori, Fiona Fleck
Aug 21, 2014·The New England Journal of Medicine·Andreas H DiaconUNKNOWN TMC207-C208 Study Group
Mar 20, 2015·PloS One·Kocfa Chung-DelgadoAntonio Bernabe-Ortiz
Mar 27, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Erica LessemDalene von Delft
Jul 15, 2015·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·N NdjekaY Pillay
Citations
Nov 1, 2016·The Journal of Antimicrobial Chemotherapy·Moloko C CholoRonald Anderson
Nov 18, 2016·American Journal of Respiratory and Critical Care Medicine·Elizabeth P HarauszUNKNOWN Sentinel Project on Pediatric Drug-Resistant Tuberculosis
Jun 1, 2017·Expert Review of Respiratory Medicine·Ignacio MonederoAdrián Sánchez-Montalvá
Mar 24, 2017·The European Respiratory Journal·Emanuele PontaliGiovanni Battista Migliori
Jul 16, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yuhong LiuYu Pang
May 4, 2017·ELife·Madhukar Pai, Jennifer Furin
May 15, 2018·Frontiers in Cellular and Infection Microbiology·H M Adnan HameedTianyu Zhang
Oct 13, 2019·European Respiratory Review : an Official Journal of the European Respiratory Society·Edine TiemersmaMichael Kimerling
Oct 21, 2016·Expert Review of Anti-infective Therapy·Jan-Willem C AlffenaarDick Van Soolingen
Dec 15, 2020·Emerging Topics in Life Sciences·Khaled H AlzahabiAlexandra E Porter
Aug 28, 2021·Antimicrobial Resistance and Infection Control·Cong YaoYu Pang